Milestone Medical's Hong Kong IPO and domestic unlisted shares' "full circulation" obtains approval from the China Securities Regulatory Commission.

The International Cooperation Department of the China Securities Regulatory Commission issued a notice on the record of the overseas public offering and listing of Shenzhen Maitian Biotechnology Co., Ltd. and the "full circulation" of unlisted domestic shares. The company plans to issue no more than 191,557,800 shares of overseas listed common stock and list on the Hong Kong Stock Exchange. A total of 49 shareholders of the company intend to convert their combined 440,311,086 shares of unlisted domestic shares into overseas listed shares and list them for circulation on the Hong Kong Stock Exchange.